Literature DB >> 14502537

Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport.

Sanna Tolle-Sander1, Andreas Grill, Hemant Joshi, Ram Kapil, Stefano Persiani, James E Polli.   

Abstract

The objective of this work was to characterize dexloxiglumide biopharmaceutical properties in vitro and relate these characteristics to its in vivo absorption performance, and to assess dexloxiglumide interaction with P-glycoprotein (P-gp) and MRP1 to anticipate its drug interaction potential. Dexloxiglumide aqueous solubility was moderate and pH dependent. Dexloxiglumide exhibited moderate Caco-2 permeability that was polarized, concentration dependent, and pH dependent. The apical-to-basolateral (AP-BL) permeability at pH 5 [14.5 (+/-1.8) x 10(-6) cm/s] was 2-fold higher than at pH 7.5 [7.24 (+/-0.27) x 10(-6) cm/s]. Neutral and ionized dexloxiglumide species displayed permeabilities of 30.8 (+/-8.4) x 10(-6) cm/s and 9.03 (+/-1.31) x 10(-6) cm/s, respectively. The transport of dexloxiglumide across MDR1-MDCK (P-gp overexpressing Madine Darby canine kidney cells) monolayers was polarized, with a BL-AP/AP-BL permeability ratio of 9.35 (+/-0.73), which was reduced to 1.03 (+/-0.03) by P-gp inhibition. Rhodamine 123 efflux was reduced by dexloxiglumide from 4.06 (+/-0.34) to 2.84 (+/-0.15) across Caco-2 monolayers, and from 17.3 (+/-0.9) to 8.26 (+/-1.38) across MDR1-MDCK monolayers, further indicating dexloxiglumide interaction with P-gp. Additionally, P-gp ATPase activity increased with dexloxiglumide concentration. Dexloxiglumide was effluxed from MRP1-NIH3T3 cells (NIH-3T3 cells expressing the multidrug resistance-associated protein 1). Dexloxiglumide increased MRP1-substrate fluorescein uptake 4-fold, and fluorescein increased dexloxiglumide uptake 1.8-fold. Overall, in vitro transport studies indicate dexloxiglumide to be moderately soluble and moderately permeable, which is in agreement with the incomplete oral absorption of dexloxiglumide. In vitro, dexloxiglumide was moderately modulated by P-gp and MRP1, which provides a rationale for the design of drug interaction studies. Copyright 2003 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502537     DOI: 10.1002/jps.10428

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

Review 1.  Pharmacokinetic profile of dexloxiglumide.

Authors:  Stefano Persiani; Massimo D'Amato; Abhijeet Jakate; Partha Roy; Julie Wangsa; Ram Kapil; Lucio C Rovati
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers.

Authors:  Zeynep S Teksin; Paul R Seo; James E Polli
Journal:  AAPS J       Date:  2010-03-12       Impact factor: 4.009

3.  A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.

Authors:  Fabio Broccatelli; Emanuele Carosati; Annalisa Neri; Maria Frosini; Laura Goracci; Tudor I Oprea; Gabriele Cruciani
Journal:  J Med Chem       Date:  2011-02-22       Impact factor: 7.446

4.  Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide.

Authors:  Abhijeet S Jakate; Partha Roy; Alpita Patel; Wattanaporn Abramowitz; Stefano Persiani; Julie Wangsa; Ram Kapil
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.